David J. Kwiatkowski
Harvard University
H-index: 148
North America-United States
Top articles of David J. Kwiatkowski
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Influence of TP53 Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in STK11-Mutant Non–Small … | JCO Precision Oncology | Abdul Rafeh Naqash Charalampos S Floudas Etan Aber Asaf Maoz Amin H Nassar | 2024/2 |
Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy | Cancer cell | Elias Bou Farhat Elio Adib Melissa Daou Elizabeth P Henske Abdul Rafeh Naqash | 2024/1/8 |
PRECISION 1: A phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2. | Gopa Iyer David J Kwiatkowski Li Ding Anita N Schmid Willis H Navarro | 2024/2/1 | |
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study | Journal of Thoracic Oncology | Amin H Nassar So Yeon Kim Jacqueline V Aredo Jamie Feng Frances Shepherd | 2024/1/24 |
Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update | Journal of Clinical Oncology | Andrew J Wagner Vinod Ravi Richard F Riedel Kristen Ganjoo Brian A Van Tine | 2024/3/1 |
Real-world analysis of patients with advanced gastrointestinal (GI) cancers harboring inactivating TSC1 and TSC2 alterations using the Foundation Medicine … | Dustin A Deming Norma Alonzo Palma Willis H Navarro Gopa Iyer David J Kwiatkowski | 2024/1/20 | |
Analysis of inactivating TSC1 and TSC2 alterations in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine … | Gopa Iyer Norma Alonzo Palma Willis H Navarro David J Kwiatkowski | 2024/2/1 | |
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial | Nature Medicine | Jamie E Chaft Filiz Oezkan Mark G Kris Paul A Bunn Ignacio I Wistuba | 2024 |
Abstract B011: Phase 2, multicenter, open-label basket trial of nab-sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2 … | Clinical Cancer Research | Debra L Richardson Gopa Iyer Li Ding Anita N Schmid Willis Navarro | 2024/3/1 |
Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural … | Djalila Mekahli Roman-Ulrich Müller Matko Marlais Tanja Wlodkowski Stefanie Haeberle | 2024/3/5 | |
Abstract LB_B12: Phase 2, multicenter, open-label basket trial of nab-Sirolimus for malignant solid tumors harboring pathogenic inactivating alterations in TSC1 and TSC2 … | Molecular Cancer Therapeutics | Candace Haddox Gopa Iyer Michael J Demeure Li Ding Anita N Schmid | 2023/12/1 |
Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer. | Mehrdad Rakaee Masoud Tafavvoghi Elio Adib Biagio Ricciuti Joao Victor Machado Alessi | 2023/6/1 | |
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial | Annals of Oncology | Mehrdad Rakaee S Andersen K Giannikou E-E Paulsen Thomas Karsten Kilvær | 2023/7/1 |
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer | Cancer discovery | Lars D Engstrom Ruth Aranda Laura Waters Krystal Moya Vickie Bowcut | 2023/11/1 |
Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)/transcriptional enhancer activator domain (TEAD), in … | Cancer Research | Timothy A Yap David J Kwiatkowski Jayesh Desai Ibiayi Dagogo-Jack Michael Millward | 2023/4/14 |
Epigenomic charting and functional annotation of risk loci in renal cell carcinoma | Nature communications | Amin H Nassar Sarah Abou Alaiwi Sylvan C Baca Elio Adib Rosario I Corona | 2023/1/21 |
Lymphangioleiomyomatosis (LAM) cell atlas | Thorax | Yina Du Minzhe Guo Yixin Wu Andrew Wagner Anne Karina Perl | 2023/1/1 |
mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion | Nature Communications | Heng-Jia Liu Heng Du Damir Khabibullin Mahsa Zarei Kevin Wei | 2023/3/3 |
P1. 25-16 Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study | Journal of Thoracic Oncology | C Presley DH Owen A Nicholas S Hilz F Oezkan | 2023/11/1 |
High‐dose IV magnesium in mesothelioma patients receiving surgery with hyperthermic intraoperative cisplatin: Pilot studies and design of a phase II randomized clinical trial | Journal of Surgical Oncology | Shruti Gupta Sophia L Wells Arunima M Jose Robert H Seitter Lea Feghali | 2023/12 |
